01384nas a2200301   4500000000100000008004100001260001300042653002600055653004100081653003000122653001100152653002300163653001200186653001700198653001400215100001200229700001500241700001300256700001100269700001300280700001200293700006600305245006400371300000900435490000700444520061700451022001401068       2004                            d  c2004 Feb10aAnti-Infective Agents10aDrug Resistance, Multiple, Bacterial10aDrug Therapy, Combination10aHumans10aLeprostatic Agents10aleprosy10aLevofloxacin10aOfloxacin1 aGidoh M1 aNamisato M1 aKumano K1 aGoto M1 aNogami R1 aOzaki M1 aCommitee for standards on therapeutic usage of newquinolones 00a[Guideline for the treatment of leprosy by new quinolones].  a65-70 v733 a<p>Ofloxacin(OFLX) is often applied today as a substitution drug of MDT for drug resistance to dapsone, rifampicin or clofazimine. However, OFLX resistance is also becoming a great concern. Low and/or irregular administration are considered to be the major causes of OFLX resistance. OFLX should be used as a combined therapy, and minimal daily dose of 400 mg of OFLX or 200-300 mg of levofloxacin is required. Quinolone resistance should be considered when no improvement of clinical and/or bacterial index is observed after the treatment for 6 months. In such cases, resistance gene detection is necessary.</p>  a1342-3681